Holen Sie sich die Stockscreener-App
88.55
2.38%
-2.16
Handel nachbörslich:
88.55
Schlusskurs vom Vortag:
$90.71
Offen:
$91.56
24-Stunden-Volumen:
515.77K
Relative Volume:
0.55
Marktkapitalisierung:
$4.95B
Einnahmen:
$1.34M
Nettoeinkommen (Verlust:
$-173.66M
KGV:
-21.40
EPS:
-4.1385
Netto-Cashflow:
$-130.49M
1W Leistung:
-8.53%
1M Leistung:
-21.02%
6M Leistung:
+11.23%
1J Leistung:
+147.07%
1-Tages-Spanne:
$88.33
$92.89
1-Wochen-Bereich:
$88.33
$100.47
52-Wochen-Spanne:
$32.22
$117.88
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
88.55 | 4.95B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Dianthus Therapeutics, Inc. (DNTH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering? - Yahoo Finance
Bank of America Corp DE Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run - finance.yahoo.com
Engineers Gate Manager LP Reduces Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells 20,000 Shares - MarketBeat
Dianthus Therapeutics (DNTH) Stock Analysis: Exploring a 39% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Dianthus (NASDAQ: DNTH) officer set to sell 20,000 shares - Stock Titan
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $1.03 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at JPMorgan Chase & Co. - MarketBeat
JPMorgan Initiates Coverage on Dianthus Therapeutics With Overweight Rating - finance.yahoo.com
Dianthus Therapeutics at Cantor conference: pipeline gains speed By Investing.com - Investing.com South Africa
DNTH: Claseprubart's strong clinical results and pipeline advances are driving rapid growth and expansion - TradingView
Dianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart Advancement - Seeking Alpha
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen - Yahoo Finance
Dianthus Therapeutics R&D Head Randhawa Simrat Retains 4,000 Shares After Exercising and Selling Options - Kalkine Media
Dianthus gains new Buy from Citi on multi-blockbuster potential for lead drug - Seeking Alpha
Citigroup Initiates Dianthus Therapeutics at Buy With $156 Price Target - finance.yahoo.com
Dianthus Therapeutics EVP Simrat Randhawa Executes Stock Options and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Officer at Dianthus (NASDAQ: DNTH) lines up 2026 stock sale after option exercise - Stock Titan
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
Dianthus Therapeutics to Participate in Three Investor Conferences During September - The Manila Times
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case - Seeking Alpha
Dianthus (DNTH) Quarterly Figures: Profit Per Share Falls Below Its Benchmark for the Current Session - vinanet.vn
Bank of America Corp DE Trims Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Eagle Health Investments LP Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighStill a Buy? - MarketBeat
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com Australia
Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics director Simon Read sells $326,553 in stock - Investing.com
Dianthus (DNTH) Stock: Ends Down by 2.20% at $113.00 at the Close; Market Levels: the Supplied Trading Band Runs From $107.35 to $118.65 at the ClosePre-Earnings Momentum - vinanet.vn
Handelsbanken Fonder AB Invests $1.49 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics Director Simon Read Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - Kalkine Media
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TimesSquare Capital Management LLC Acquires Shares of 166,357 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
SCS Capital Management LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Stifel Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $133 - Moomoo
Walleye Capital LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics SVP Adam M. Veness Exercises 15,000 Stock Options at $18.17 Each - Kalkine Media
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 114.64 USD - Investing.com
Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH) - Stock Titan
Dianthus Therapeutics (DNTH): Wellington group discloses 3.23M-share, 5.9% passive stake - Stock Titan
Dianthus therapeutics director Simon Read sells $304k in stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock By Investing.com - Investing.com Nigeria
Dianthus therapeutics director Simon Read sells $304k in stock - Investing.com
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock - Investing.com
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):